{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:06:45Z","timestamp":1794200805837,"version":"4.8.0"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Good overall survival rates of about 90% are the result of improvements in risk stratification and risk-adapted therapy, intensive chemotherapy regimens, hematopoietic stem cell transplantation, and better supportive care. Background and Objectives: The aim of this study is to review the epidemiology, prognostic factors, and causes of death in pediatric ALL patients treated at a tertiary care center, and to identify risk factors influencing clinical outcomes. Materials and Methods: A retrospective study was conducted at the Department of Pediatric Hematology and Oncology, University Hospital Centre Zagreb, including 302 children (0\u201318 years) diagnosed with ALL between January 2001 and December 2015. Results: Two hundred fifty-one children survived (5-year overall survival 83%). Relapse occurred in 13.6% of patients. Relapse rates were higher for B-cell precursor (Bcp)-ALL than for T-cell ALL (14.3% vs. 10.4%), and no patient with relapsed T-cell ALL survived. The main causes of death were refractory\/relapsed disease (43% of patients), followed by infections (35%) and GVHD (8%). The most frequent causes of infectious death were Pseudomonas aeruginosa and Aspergillus fumigatus. The most critical treatment periods were the induction and reinduction phases, especially the de-escalation of corticosteroids. The time of relapse and risk group were independent factors in predicting the outcome. Conclusions: Relapse and infections were the leading causes of death in children with ALL, with the highest mortality observed during induction and reinduction phases. Survival was significantly influenced by relapse timing and risk group, with no survivors among relapsed T-ALL patients.<\/jats:p>","DOI":"10.3390\/medicina61071193","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:18:36Z","timestamp":1751264316000},"page":"1193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Causes of Death in Childhood Acute Lymphoblastic Leukemia: A Single-Center Experience"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-180X","authenticated-orcid":false,"given":"Matej","family":"Jeli\u0107","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Pavlovi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucija","family":"Mucavac","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dejanovi\u0107 Beki\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-4974","authenticated-orcid":false,"given":"Zrinko","family":"\u0160alek","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Mati\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-7489","authenticated-orcid":false,"given":"Daniel","family":"Turudi\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-6930","authenticated-orcid":false,"given":"Luka","family":"Lovren\u010di\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-6069","authenticated-orcid":false,"given":"Jelena","family":"Roganovi\u0107","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Zagreb, 16 Vjekoslava Klaica 16, 10000 Zagreb, Croatia"},{"name":"Faculty of Biotechnology and Drug Development, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-118X","authenticated-orcid":false,"given":"Ernest","family":"Bili\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12098-015-1695-5","article-title":"Leukemias in Children","volume":"82","author":"Seth","year":"2015","journal-title":"Indian J. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukemia","volume":"381","author":"Inaba","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1002\/cncr.30899","article-title":"Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study","volume":"123","author":"Tai","year":"2017","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.22.01760","article-title":"Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-M\u00fcnster 2009 Trial","volume":"41","author":"Campbell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111356","DOI":"10.1016\/j.isci.2024.111356","article-title":"Global, regional, and national burden of acute lymphoblastic leukemia in children: Epidemiological trends analysis from 1990 to 2021","volume":"27","author":"Hu","year":"2024","journal-title":"IScience"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.13847","article-title":"Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: Results from UKALL 2003","volume":"172","author":"Hough","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_9","first-page":"172","article-title":"Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002","volume":"32","author":"Stary","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12562","article-title":"Toxicity profile and treatment delays in NOPHO ALL2008\u2014Comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"96","author":"Toft","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997\u20132004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): A randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Stolpa, W., Zapa\u0142a, M., Zwiernik, B., and Mizia-Malarz, A. (2022). Relapses Children\u2019s Acute Lymphoblastic Leukemia, Single Center Experience. Children, 9.","DOI":"10.3390\/children9121874"},{"key":"ref_15","first-page":"1090","article-title":"Clinical features and long-term prognostic analysis of relapsed pediatric acute lymphoblastic leukemia","volume":"62","author":"Wang","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: A Children\u2019s Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2010-07-294678","article-title":"Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: A report from the Children\u2019s Oncology Group","volume":"117","author":"Freyer","year":"2016","journal-title":"Blood J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2333794X20901930","DOI":"10.1177\/2333794X20901930","article-title":"Causes of Death in Childhood Acute Lymphoblastic Leukemia at Hue Central Hospital for 10 Years (2008\u20132018)","volume":"7","year":"2020","journal-title":"Glob. Pediatr. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/17474086.2015.1071186","article-title":"Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries","volume":"8","author":"Caniza","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(23)00318-2","article-title":"Treatment-related mortality in children with cancer in low-income and middle-income countries: A systematic review and meta-analysis","volume":"24","author":"Ehrlich","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MPH.0000000000000760","article-title":"Long-term results of the risk-adapted treatment for childhood B-cell acute lymphoblastic leukemia: Report from the Japan association of childhood leukemia study ALL-97 trial","volume":"39","author":"Horibe","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"865979","DOI":"10.1155\/2014\/865979","article-title":"Characterization of Pediatric Acute Lymphoblastic Leukemia Survival Patterns by Age at Diagnosis","volume":"2014","author":"Hossain","year":"2014","journal-title":"J. Cancer Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","article-title":"Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children\u2019s Oncology Group (COG) study","volume":"37","author":"Rheingold","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in Children with Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children\u2019s Oncology Group Trial AALL0331","volume":"38","author":"Maloney","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"188","article-title":"Infections during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia\u2014Profile and Outcomes: Experience from a Cancer Center in South India","volume":"39","author":"Rajeswari","year":"2021","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdw557","article-title":"Infection-related complications during treatment for childhood acute lymphoblastic leukemia","volume":"28","author":"Inaba","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MPH.0000000000001926","article-title":"In-Hospital Management Might Reduce Induction Deaths in Pediatric Patients with Acute Lymphoblastic Leukemia: Results From a Japanese Cohort","volume":"43","author":"Nakagawa","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPH.0000000000001468","article-title":"Frequency and Determinants of Invasive Fungal Infections in Children with Solid and Hematologic Malignancies in a Nonallogeneic Stem Cell Transplantation Setting: A Narrative Review","volume":"41","author":"Ruijters","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_31","first-page":"12","article-title":"Letters to the Editor: Defining Invasive Fungal Infection Risk in Hematological Malignancies: A New Tool for Clinical Practice","volume":"9","author":"Rambaldi","year":"2017","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1099\/mic.0.000620","article-title":"Relationship of environmental disturbances and the infectious potential of fungi","volume":"164","author":"Hernandez","year":"2018","journal-title":"Microbiology"},{"key":"ref_33","first-page":"433","article-title":"Review of Fungal Outbreaks and Infection Prevention in Healthcare Settings During Construction and Renovation","volume":"61","author":"Kanamori","year":"2015","journal-title":"Helathcare Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Iwasaki, M., Kanda, J., Hishizawa, M., Kitano, T., Kondo, T., Yamashita, K., and Takaori-Kondo, A. (2019). Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: A retrospective cohort study. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-018-3665-9"},{"key":"ref_35","first-page":"1","article-title":"Relapsed Childhood Acute Lymphoblastic Leukemia: A Single-Institution Experience","volume":"12","author":"Tuong","year":"2020","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jped.2018.07.013","article-title":"Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: High mortalities, early relapses, and poor survival","volume":"96","author":"Abdelmabood","year":"2018","journal-title":"J. Pediatr. (Rio J.)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MPH.0b013e31829f3235","article-title":"Treatment of Relapsed Precursor-B Acute Lymphoblastic Leukemia with Intensive Chemotherapy: POG (Pediatric Oncology Group) Study 9411 (SIMAL 9)","volume":"35","author":"Kelly","year":"2013","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Reiter","year":"2008","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): A prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"Kotecha","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:52Z","timestamp":1760032912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071193"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071193","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}